UNSPSC 51432607: Monatepil maleate

This classification denotes a calcium channel blocker with the molecular formula C28H30FN3OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W456I35SKD. The term monatepil maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule monatepil maleate under HS 29349990 and SITC 51579. As of Q4 2014, MONATEPIL MALEATE remains US FDA's Preferred Term for this commodity. Monatepil maleate bears US NLM identifiers UMLS ID C0246444 and NCI Concept Code C81688.

SMILES: C1CCC2C(C1)CSC3CCCCC3C2NC(=O)CCCN4CCN(CC4)C5CCC(CC5)F.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51432607 Monatepil maleate, a Commodity code, represents pharmaceutical supply contracting by state and local public health agencies, fire departments, and health benefit administrators for emergency life-support medications and generic multi-source drug products. The code captures active procurement of branded and generic pharmaceuticals sourced through both direct vendor supply and authorized pharmaceutical wholesalers, with recent solicitations emphasizing compliance with cGMP, DSCSA, FDA requirements, and detailed product specifications including NDC codes, dosage forms, and expiration-date floors. State and local buyers under this code include city fire and rescue departments, state health and human services agencies, and multi-state cooperative purchasing organizations that aggregate demand across member jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (26P00188) in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities and Oregon, requiring vendors to work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with a contract start of July 1, 2026. Tampa's solicitation carries a 5 percent Small Local Business Enterprise bid discount, and all opportunities require Safety Data Sheets and OSHA HCS compliance documentation.